Clinical Trial

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Name: A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma — clinical trial record (NCT05814848)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-04-13.

Trial Details

NCT Number	NCT05814848
Lead Sponsor	Changhai Hospital
Conditions	Relapsed or Refractory B-cell Lymphoma
Enrollment	13 participants
Start Date	2023-06-20
Primary Completion	2028-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2023-06-15